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Aim Coinfecting bacterial pathogens are a major cause of morbidity
and mortality in influenza. However, there remains a paucity of
literature on the magnitude of coinfection in influenza patients.
Method A systematic search of MeSH, Cochrane Library, Web of
Science, SCOPUS, EMBASE, and PubMed was performed. Studies
of humans in which all individuals had laboratory confirmed
influenza, and all individuals were tested for an array of common
bacterial species, met inclusion criteria.
Results Twenty-seven studies including 3215 participants met all
inclusion criteria. Common etiologies were defined from a subset of
eight articles. There was high heterogeneity in the results
(I2 = 95%), with reported coinfection rates ranging from 2% to
65%. Although only a subset of papers were responsible for observed
heterogeneity, subanalyses and meta-regression analysis found no
study characteristic that was significantly associated with
coinfection. The most common coinfecting species were
Streptococcus pneumoniae and Staphylococcus aureus, which
accounted for 35% (95% CI, 14%–56%) and 28% (95% CI, 16%–
40%) of infections, respectively; a wide range of other pathogens
caused the remaining infections. An assessment of bias suggested
that lack of small-study publications may have biased the results.
Conclusions The frequency of coinfection in the published studies
included in this review suggests that although providers should
consider possible bacterial coinfection in all patients hospitalized
with influenza, they should not assume all patients are coinfected
and be sure to properly treat underlying viral processes. Further,
high heterogeneity suggests additional large-scale studies are needed
to better understand the etiology of influenza bacterial coinfection.
Keywords antibiotic resistance, bacterial coinfection, influenza,
meta-analysis, MRSA, Streptococcus Pneumoniae.
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What this adds to existing literature
Clinical treatment of influenza presents difficulties because of
significant uncertainty regarding the probability of bacterial
coinfection. Despite this uncertainty, the frequency of overall
coinfection in influenza patients is still poorly characterized.
This meta-analysis increases understanding of the likelihood
that patients hospitalized with influenza also have a bacterial
coinfection; however, the variability in results suggests that
physicians should ensure that appropriate cultures are taken
to minimize the overuse of antibiotics.
Introduction
Influenza causes widespread annual epidemics infecting up
to 20% of the population and resulting in significant
morbidity and mortality.1 Coinfecting bacterial pathogens
are a major cause of that morbidity and mortality and are
associated with both pandemic and seasonal influenza
virus illness.2 Lung tissue samples from the 1918 influenza
pandemic suggest that the majority of the estimated 20–60
million deaths were from bacterial infections rather than
from direct effects of the virus.3 In seasonal epidemics,
influenza bacterial coinfection is associated with increases
in hospital admissions,4,5 more severe symptoms,6 and
increases in mortality.7 Viral damage to the epithelial
lining of the respiratory tract is believed to facilitate
establishment of bacterial infections.8–10 However, other
factors, such as changes in airway function, up-regulation
and exposure of receptors, dampening of the immune
response, or enhancement of inflammation may also play a
role.11
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Clinically, it can be difficult to identify influenza patients
experiencing bacterial coinfections, given the substantial
symptom overlap of influenza and bacterial infections.
Identification of coinfected patients and coinfecting patho-
gen enables clinicians to initiate appropriate antibiotic
therapy and improve patient outcomes.12 While prior studies
have examined the frequency of select bacterial species in
influenza cases,13,14 particularly the presence of methicillin-
resistant S. aureus (MRSA),15–18 the frequency of overall
coinfection in influenza patients is still poorly characterized.
We undertook a systematic review to determine the
frequency of bacterial coinfections in patients with laboratory
confirmed influenza and to identify the most common
coinfecting bacterial species.
Methods
We conducted a systematic review, which is reported in
accordance with PRISMA guidelines,19 to determine the
frequency of bacterial coinfection among individuals with
laboratory confirmed influenza. Inclusion was restricted to
studies of humans in which all individuals had laboratory
confirmed influenza, and all individuals were tested for an
array of common bacterial species. Studies reanalyzing prior
published data were excluded. There were no limitations
based on participant age or the location of participant
recruitment (i.e., community, outpatient, hospital). Coin-
fection was assumed to be any acute bacterial infection
identified in respiratory secretions, sputum, or sterile site
(e.g., bacteremia). We restricted results to publications in
English published after January 1982. To avoid analyses of
historic samples, particularly related to the influenza pan-
demic of 1968, studies using data collected prior to 1972 were
excluded. Case reports, defined as studies with a sample size
of fewer than 10 individuals, were excluded, but no other
limitations based on study design were imposed.
Literature search
Weperformed a systematic search ofMeSH,Cochrane Library,
Web of Science, SCOPUS, EMBASE, and PubMed for
publications in August 2014. The search terms included
influenza, bacterial infection, bacterial coinfection, bacterial
pathogens, bacteremia, bacterial–viral infection, coinfection,
secondary infection, mixed infection, concomitant infection,
H1N1, swine influenza, bird flu, gripe, pandemic influenza,
seasonal influenza, influenza virus A H1N1, and avian
influenza. The complete search strategy, which was completed
in consultationwith a research librarian, is detailed in Table S1.
Selection of studies
Two authors (BM, AG) independently screened the title and
abstract of all the search-returned publications to determine
whether they met study criteria. The full text of all studies
meeting the criteria and those for which a conclusion could
not be made were reviewed independently by the two
authors. Disagreements were resolved through consultation
with a third party.
Data extraction
A structured data extraction form was used to collect data
elements of each study into a Microsoft Excel worksheet.
Two authors (BM, AG) extracted study data from all
included publications independently, and results were then
compared. Differences were resolved by consensus. Informa-
tion extracted included: study design (i.e., prospective,
retrospective), location of the study, study size, year of
enrollment, study enrollment setting (i.e., intensive care unit
[ICU], hospital, or emergency department [ED]), influenza
strain (A, A pH1N1, B, all), participant age, bacterial
collection method (sputum, blood, bronchial alveolar lavage
[BAL]), method of bacterial detection (stain, culture, poly-
merase chain reaction [PCR], antibody), bacterial species
evaluated, and bacterial species identified. In cases where
only a percentage or subject number was published, its
counterpart was calculated for analysis in the current review.
Sources of data were carefully reviewed by BM, AG, EK, and
studies reporting already included data were excluded (the
study with the earlier publication date was considered the
primary study, and all others excluded).
Assessment of bias
The potential bias of each study was assessed using the
Quality Assessment Tool for Quantitative Studies developed
by the National Collaborating Centre for Methods and
Tools.20 This tool was selected for its comprehensive ability to
assess the methodological quality of non-randomized studies
and has shown good reliability and validity.21,22 A 3-point
scale was used for the following criteria: selection bias, study
design, confounders, blinding, data collection methods, and
study withdrawals. A global rating of “strong” was awarded
for 4 “strong” ratings and no “weak” ratings, “moderate” for
less than four “strong” and one “weak,” and “weak” for two
or more “weak” ratings. Each study was independently
evaluated by two authors, and discrepancies regarding bias
assessment were resolved by consensus. Funnel plots and
calculation of Egger’s test of asymmetry were also used to
assess biases such as publication and small-study effects.23
Data analysis
The primary outcome was the proportion of bacterial
coinfection. Coinfection was defined as the number of
cases with a confirmed bacterial coinfection in all tested
cases of patients with laboratory confirmed influenza.
Because of differences between studies, we analyzed
combined data on coinfection frequencies using the
DerSimonian-Laird method in the metaphor package,24 a
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meta-analysis package for R.25 Heterogeneity was quanti-
fied using the I2 statistic.26 Least-squares meta-regressions
were performed to investigate the effect of differences in a
priori defined trial-level characteristics on the frequency of
coinfection.27 These included: (i) age of the participants;
(ii) study enrollment setting; (iii) year of enrollment; (iv)
retrospective or prospective study design; (v) study size;
(vi) bacterial collection method (BAL versus other); and
(vii) method of bacterial detection. For bacterial detection,
we examined the types of tests used to detect bacteria
individually as well as the total number of tests used. To
investigate the heterogeneity between studies and the
influence of studies on the results, we performed a leave-
one-out analysis as well as used Cook’s distances to group
the most heterogeneous studies. For species-level analysis,
only studies providing the numbers or percentages of each
bacterial coinfecting pathogen were included. We included
all pathogens in cases where more than one bacterial
pathogen was found.
Results
Study screening and selection
The initial literature search yielded 1122 references, which
was reduced to 1034 after removing duplicates. Following
initial abstract review, 101 articles remained. The full-text
review resulted in the exclusion of an additional 74 articles. A
total of 27 articles encompassing 3215 patients met all the
inclusion criteria and were included in the final analysis.28–54
Of those 27, only eight studies, with 334 patients, provided
the numbers or percentages of each bacterial coinfecting
pathogen.28,32–34,38,43,46,47 Thus, these eight studies formed
the basis for identifying the most common coinfecting
bacterial pathogens (Figure 1).
Figure 1. Flow diagram of study selection.
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Study characteristics
All 27 included studies were observational, of which 13 (1218
patients) were prospective studies,30,32,33,36,40,41,43,44,48–52 and
14 (1997 patients) were retrospective analyses (Table 1). The
majority (21) of studies were cohort studies, and the
rest were case–control studies. Fifteen of the studies
(1885 patients) began enrollment in 2009 or
later,28,32–35,37,39,41,42,44,46,48,49,53,54 and of these, all but one
was specifically focused on the 2009 H1N1 pandemic strain.
Most studies enrolled only adults, although the lower age
cutoffs varied (e.g., some studies considered adults older than
14 while others used 21). Only seven studies (1214 patients)
focused on young children or newborns,29,31,38,46,49,51,54 and
two studies (504 patients) included both children and
adults.42,53 Severity of illness varied among studies, but all
were focused on hospitalized patients, suggesting a greater
than average severity. Eleven of the studies (1007 patients)
focused exclusively on patients initially enrolled in
an intensive care unit (ICU),32,34,35,38,39,41,42,44,46,47,51 10
enrolled non-ICU hospitalized patients (973
patients),30,33,36,37,40,43,45,49,53,54 3 enrolled patients in the
emergency department (ED; 135 patients),28,48,50 and 2
enrolled patients in a mix of inpatient and outpatient
settings (1100 patients).29,52 The median sample size was 51
(IQR, 185–101), and the mean was 119 (SD: 203), which was
driven by three large studies29,44,53 that contributed 1958
(61%) of the total number of patients included in this
analysis.
Assessment of bias
The average quality of the studies was moderate, with the
most common quality issues being related to study design,
selection biases, and data collection (Table S2). While studies
were generally representative of the targeted population,
most studies did not report the percentage of patients that
agreed to participate. This lack of detail did not allow us to
eliminate the possibility of selection bias in the study cohorts.
Studies were also not fully clear on the reliability of the tools
used for data collection, which made it difficult to eliminate
this as a potential source of bias in the strains detected.
However, results from the bias assessment suggest that the
largest potential source of bias was the fact that all the studies
were observational studies, and most were small cohort
studies. A funnel plot appeared asymmetrical (Figure 2),
suggesting statistical heterogeneity; in particular, there seems
to have been a lack of smaller studies with lower rates of
bacterial coinfection. Egger’s test of asymmetry was also
significant for bias (P = 00004).
Bacterial coinfection
Among the individual studies, the proportion of bacterial
coinfection ranged from 2% (newborns born in USA) to 65%
(immunocompetent adults in France) (Figure 3). High
statistical heterogeneity of the included studies (I2 = 95%)
removed confidence in reporting an estimate of the pooled
mean proportion of bacterial coinfection through meta-
analysis. Using Cook’s distances to identify studies that most
greatly affected the heterogeneity and results, we found that
seven studies contributed more than 50% of the heterogene-
ity.29,31,34,39,40,45,46 The proportion of bacterial coinfection
among the remaining 20 studies, representing 64% of all
patients, was between 11% and 35% (I2 = 37%). Subanalyses
and meta-regression of age, setting, year of enrollment, study
type, study size, and bacterial collection method were unable
to determine the main sources of heterogeneity. Although
heterogeneity was greater in the pediatric studies (I2 = 98%)
than in the adult studies (I2 = 89%), coinfection frequency
was statistically the same (P = 047). No significant trend was
seen when stratifying the studies by mean or median age
(Figure S1). Patients enrolled in the ICU had a slightly higher
frequency of coinfection than patients enrolled elsewhere,
although this was also not statistically significant (P = 014).
Despite the fact that the study period included the 2009 H1N1
pandemic, we observed no significant effect of enrollment
year on the frequency of coinfection (P = 019, Figure S2).
The largest study contributed greatly to the heterogeneity of
the results; however, study size did not significantly con-
tribute to the heterogeneity in the results (P = 006 with the
largest study, while P = 041 excluding this study). Finally,
study design (P = 047) and bacterial coinfection collection
and detection methods (each was tested independently and all
P-values were greater than 005) were also not significant. A
multivariate analysis also found no significant correlation
between any of the variables and overall rates of coinfection.
Several factors may have contributed to heterogeneity
between the selected studies that we were unable to quantify.
Only four studies explicitly measured and reported on
comorbidities of patients with coinfection and found that
older age,28,44,53 a higher APACHE II (Acute Physiology and
Chronic Health Evaluation II) score,44,53 diabetes,33 and
sepsis33 were risk factors for coinfection. Further, some
studies only included severely immunocompromised patients
who had concurrent malignancy or organ transplant,31,33,49
while others excluded immunocompromised patients. Sever-
ity of illness however was not a factor that could be
standardized among the studies.
Antibiotic use at the time of, or prior to enrollment, was
another factor that may have contributed to significant
heterogeneity, but could not be systematically assessed. Only
three studies excluded participants based on antibiotic use
and reported coinfection rates of 122%, 267%, and
466%.28,34,36 An additional six studies reported on partic-
ipant antibiotic use at the time of enrollment and found
that 12–50% of patients had preceding antibiotic treat-
ment which may have led to an underestimation of the
true frequency of bacterial coinfection in their sample
Influenza–bacterial coinfection
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population.30,33,40,45,47,52 For example, Bjarnason and col-
leagues found that none of the patients using antibiotics were
in the coinfected group and when they excluded antibiotic
users from the study, the prevalence of coinfection increased
from 14% to 45%.30 One study found that previous
antibiotic use made patients more likely to acquire atypical
bacterial infections.50
Species-level analysis
Streptococcus pneumoniae and Staphylococccus aureus were the
most common pathogens accounting for 35% (95% CI, 14%–
56%) and 28% (95% CI, 16%–40%) of identified coinfecting
bacteria, respectively (Figure 4). A number of other pathogens
were also identified as causing coinfections: Pseudomonas
aeruginosa, Streptococcus pyogenes, Haemophilus influenzae,
Klebsiella pneumoniae, and Mycoplasma pneumoniae. In
addition, other Staphylococcal pathogens such as S. epider-
midis, and Gram-negative bacteria, such as Escherichia coli and
Moraxella catarrhalis, were also frequently found.
Discussion
Despite the long historical understanding of the risk posed by
bacterial coinfections in influenza patients,2 the extent of
coinfection has not been systematically examined.55 Under-
standing the risk of bacterial coinfection in hospitalized
patients with influenza can help clinicians balance the need
to minimize patient morbidity and mortality due to bacterial
infection as well as the individual and societal risks of
unnecessary antibiotic use.12 To assess the frequency of
bacterial coinfection in laboratory confirmed influenza
patients, we performed a systematic review and meta-analysis
of papers published since 1982. We found 27 studies covering
3215 patients. The results from these studies were highly
variable, ranging from 2% to 65%. Although the majority of
studies ranged between 11% and 35%, no specific charac-
teristics of the studies were associated with variability in
coinfection frequency. However, there was some suggestion
that negative findings or low levels of bacterial coinfection
were not published.
Differentiating viral from bacterial infection remains a
challenge for clinicians. This diagnostic uncertainty has
contributed to a widely recognized overuse of antibiotics in
patients with viral illness.56,57 The CDC recommends simul-
taneous antiviral and antibiotic use in the event of influenza-
related pneumonia or suspected bacterial coinfection in
patients with influenza.58 However, as previous observational
studies have shown, patients admitted to the hospital with
influenza are more likely to receive antibiotics than antiviral
medications.59,60 Our findings suggest that while patients
hospitalized with moderate to severe influenza may be
coinfected with both viral and bacterial pathogens, many
patients will likely not be coinfected. Thus, although
recognition and treatment of potential bacterial coinfections
is important, particularly community-acquired pneumonia
in which pathogens are difficult to detect,61 clinicians should
consider treatment of potential underlying viral processes as
well, particularly for high-risk patients.60 Furthermore, to
avoid overuse of antibiotics, our study suggests that routine
cultures are advisable in patients hospitalized with influenza,
particularly those started on antibiotic therapy empirically.
Antibiotic therapy may then be de-escalated as necessary
based on microbiological results.
Consistent with the prior literature,55,62 we found that
S. pneumoniae was the most frequent bacterial coinfection;
however, both S. aureus and other bacterial coinfections were
also quite common. This diverse profile of coinfecting
pathogens confirms current Infectious Disease Society of
America (IDSA) recommendations for broad-spectrum
antibiotic coverage for influenza-related pneumonia.63 How-
ever, although there have been significant increases in the
incidence of MRSA infections in the last decade, particularly
community-associated MRSA (CA-MRSA),64 there was not
enough data to draw any inferences regarding temporal
changes in the etiology of coinfecting pathogens. Given that
over 25% of identified isolates were S. aureus, and that
approximately 50% of hospital S. aureus isolates are
MRSA,64 our study supports IDSA recommendations for
empiric coverage of CA-MRSA in influenza-related pneu-
monia patients.63
The lack of a statistically significant study covariate may be
due to some of the limitations of the study. First of all,
Figure 2. Funnel plot of each study’s standard error (y-axis) against each
study’s frequency of bacterial coinfection in laboratory confirmed
hospitalized patients. Because small studies have less precision and large
studies have more, scatter should form an inverted funnel when there are
no systematic missing studies. The line indicates the overall mean
frequency of coinfection (23%). The funnel plot appears asymmetric.
Egger’s test of asymmetry was significant for bias (P = 00004).
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although our final sample size included 27 studies and more
than 3000 patients, these are relatively small numbers
compared to annual estimates of up to 200 000 influenza-
related hospitalizations.65 Second, studies included only
patients who were hospitalized for influenza and thus
represent a population with moderate to severe influenza.
Although a few studies enrolled patients in the outpatient or
ED setting, all required hospitalization. The study does not,
therefore, represent the vast majority of influenza patients,
including asymptomatic patients, who are not hospitalized.
This identifies a gap in the current literature as the frequency
of bacterial coinfection in outpatients with confirmed
influenza remains unknown. Third, studies included in this
analysis detected bacterial pathogens in a number of different
ways, which have varying sensitivity for different organisms
and potential coinfecting sites (e.g., sputum versus blood).
Some difficult-to-detect bacteria may, therefore, be
underdiagnosed. Hence, these results may underrepresent
the actual number of bacterial coinfections and the distri-
bution of the pathogens of those coinfections. Results for
bacterial distribution and likelihood of coinfection may also
be affected by colonization rather than infection; however,
studies were selected that specifically looked for bacterial
coinfection and thus the issue of colonization should be
minimal. Finally, we were unable to explain the significant
heterogeneity among studies. It was not accounted for by
differences in patient age, year, study enrollment setting,
study design, study size, or method of bacterial sample
collection or detection. This lack of statistically significant
variability may be due to unrecorded differences in the
studies, such as genetic differences in the populations, local
differences in either the severity of viral or bacterial illness,
unrecorded patient comorbidities, variation in treatment, or
as noted above, antibiotic use (either current or past).
Figure 3. Frequency of bacterial coinfection in hospitalized patients with laboratory confirmed influenza.
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The high heterogeneity and lack of statistically significant
covariates also points to the need for additional studies
aimed at better understanding rates of bacterial coinfection,
outcomes by pathogen, the effect of increased testing for both
bacterial and viral pathogens, and the efficacy of interven-
tions, such as increased use of antiviral drugs. These are
particularly important in light of recent findings that viral
pathogens were more commonly found than bacterial
pathogens in suspected community-acquired pneumonia
infections.61
Conclusion
We found that bacterial coinfection of hospitalized patients
with influenza is often common, although results were
highly heterogeneous. The predominant coinfecting organ-
ism in the studies was S. pneumoniae followed by S. aureus,
but many other organisms were also found to cause
infections. Providers should consider possible bacterial
coinfection in patients hospitalized with influenza, and
bacterial cultures should be taken to avoid patient exposure
to the risks of prolonged unnecessary antibiotic use. If
antibiotic treatment is started, possible coinfection with
MRSA should be considered, particularly for community-
acquired pneumonia infections, when selecting appropriate
antibiotics, and therapy should be discontinued or de-
escalated as indicated by microbiological results. Finally,
the frequency of coinfection should be better characterized
in the entire influenza patient population, including
outpatients, in future analyses.
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